Novel advances in biotransformation and bioactivation research - 2020 year in review
This annual review is the sixth of its kind since 2016 (see references). Our objective is to explore and share articles which we deem influential and significant in the field of biotransformation and bioactivation. These fields are constantly evolving with new molecular structures and discoveries of corresponding pathways for metabolism that impact relevant drug development with respect to efficacy and safety. Based on the selected articles, we created three sections: (1) drug design, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation and safety (Table 1). Unlike in years past, more biotransformation experts have joined and contributed to this effort while striving to maintain a balance of authors from academic and industry settings.[Table: see text].
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 53(2021), 3 vom: 04. Aug., Seite 384-433 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khojasteh, S Cyrus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioactivation |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 02.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03602532.2021.1916028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324637551 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324637551 | ||
| 003 | DE-627 | ||
| 005 | 20231225190739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2021.1916028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1082.xml |
| 035 | |a (DE-627)NLM324637551 | ||
| 035 | |a (NLM)33910427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khojasteh, S Cyrus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel advances in biotransformation and bioactivation research - 2020 year in review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 02.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This annual review is the sixth of its kind since 2016 (see references). Our objective is to explore and share articles which we deem influential and significant in the field of biotransformation and bioactivation. These fields are constantly evolving with new molecular structures and discoveries of corresponding pathways for metabolism that impact relevant drug development with respect to efficacy and safety. Based on the selected articles, we created three sections: (1) drug design, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation and safety (Table 1). Unlike in years past, more biotransformation experts have joined and contributed to this effort while striving to maintain a balance of authors from academic and industry settings.[Table: see text] | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Drug metabolism | |
| 650 | 4 | |a bioactivation | |
| 650 | 4 | |a biotransformation | |
| 650 | 4 | |a nonp450 enzymes | |
| 650 | 4 | |a p450 enzymes | |
| 700 | 1 | |a Argikar, Upendra A |e verfasserin |4 aut | |
| 700 | 1 | |a Driscoll, James P |e verfasserin |4 aut | |
| 700 | 1 | |a Heck, Carley J S |e verfasserin |4 aut | |
| 700 | 1 | |a King, Lloyd |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Klarissa D |e verfasserin |4 aut | |
| 700 | 1 | |a Jian, Wenying |e verfasserin |4 aut | |
| 700 | 1 | |a Kalgutkar, Amit S |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Grover P |e verfasserin |4 aut | |
| 700 | 1 | |a Kramlinger, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Rietjens, Ivonne M C M |e verfasserin |4 aut | |
| 700 | 1 | |a Teitelbaum, Aaron M |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Cong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d 1973 |g 53(2021), 3 vom: 04. Aug., Seite 384-433 |w (DE-627)NLM000049530 |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:3 |g day:04 |g month:08 |g pages:384-433 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03602532.2021.1916028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 3 |b 04 |c 08 |h 384-433 | ||